Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice

This Viewpoint cautions against premature adoption of the α-synuclein seed amplification assay as a biomarker test for Parkinson disease in general neurology practice.

Authors

Institutions

Publication Details

Journal
JAMA Neurology
Published
2024-08-05
DOI
https://doi.org/10.1001/jamaneurol.2024.2381
Citations
9
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
3.32
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice

Huw R. Morris, Andrew Lees
9 citations
JAMA Neurology
Parkinson's Disease Mechanisms and Treatments
3.32
article

Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice

Huw R. Morris, Andrew Lees
article en
9 citations

Abstract

This Viewpoint cautions against premature adoption of the α-synuclein seed amplification assay as a biomarker test for Parkinson disease in general neurology practice.

JAMA NeurologyVol. 81(9)
National Hospital for Neurology and Neurosurgery (GB), Research Network (United States) (US), University College London (GB)
Good health and well-being
Openalex Percentile: Top 7%
Parkinson's Disease Mechanisms and Treatments
3.32
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice — Huw R. Morris, Andrew Lees · JAMA Neurology (2024) | TGRS Research Map | TGRS